INKT vs PATH · $59.1M cap vs P/E 19, rev $1.61B
Mink Therapeutics Inc (INKT) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Mink Therapeutics Inc (INKT) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
INKT does not have a complete income-statement cache yet.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INKT currently screens at market cap $59.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INKT and PATH stock pages for the full models.
Not investment advice.